Oral anticoagulants in patients with chronic kidney disease and atrial fibrillation

The aim of this study was to investigate the effects of new/direct oral anticoagulants (DOACs) on renal function parameters in chronic kidney disease patients with esti-mated glomerular filtration rate (eGFR) that therapy with new/direct oral antico-agulants (non-VKA oral anticoagulants) have a better bleeding risk profile and less decline in eGFR compared with vitamin K antagonists.